Free Trial

Novartis (NVS) Competitors

$99.39
-0.29 (-0.29%)
(As of 05/29/2024 ET)

NVS vs. LLY, NVO, JNJ, MRK, ABBV, AZN, ABT, PFE, SNY, and VRTX

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Abbott Laboratories (ABT), Pfizer (PFE), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "pharmaceutical preparations" industry.

Novartis vs.

Novartis (NYSE:NVS) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Novartis has a net margin of 31.33% compared to Eli Lilly and Company's net margin of 17.08%. Eli Lilly and Company's return on equity of 56.98% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis31.33% 32.15% 13.59%
Eli Lilly and Company 17.08%56.98%10.94%

Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.4%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Novartis pays out 32.8% of its earnings in the form of a dividend. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novartis presently has a consensus target price of $115.00, indicating a potential upside of 15.71%. Eli Lilly and Company has a consensus target price of $769.53, indicating a potential downside of 5.32%. Given Novartis' higher possible upside, equities research analysts clearly believe Novartis is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Eli Lilly and Company
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

In the previous week, Eli Lilly and Company had 41 more articles in the media than Novartis. MarketBeat recorded 57 mentions for Eli Lilly and Company and 16 mentions for Novartis. Novartis' average media sentiment score of 0.63 beat Eli Lilly and Company's score of 0.56 indicating that Novartis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
7 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
25 Very Positive mention(s)
7 Positive mention(s)
18 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Positive

13.1% of Novartis shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eli Lilly and Company received 646 more outperform votes than Novartis when rated by MarketBeat users. Likewise, 70.07% of users gave Eli Lilly and Company an outperform vote while only 61.42% of users gave Novartis an outperform vote.

CompanyUnderperformOutperform
NovartisOutperform Votes
527
61.42%
Underperform Votes
331
38.58%
Eli Lilly and CompanyOutperform Votes
1173
70.07%
Underperform Votes
501
29.93%

Novartis has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Novartis has higher revenue and earnings than Eli Lilly and Company. Novartis is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.73B4.26$14.85B$7.4113.41
Eli Lilly and Company$34.12B22.64$5.24B$6.79119.70

Summary

Novartis and Eli Lilly and Company tied by winning 10 of the 20 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$203.15B$6.96B$5.12B$17.46B
Dividend Yield2.42%2.77%2.83%3.53%
P/E Ratio13.4121.92170.8425.51
Price / Sales4.26258.662,441.8210.12
Price / Cash9.0533.0735.2719.29
Price / Book5.115.845.515.82
Net Income$14.85B$138.41M$105.57M$975.72M
7 Day Performance-1.68%-1.24%-0.90%-1.95%
1 Month Performance2.33%1.38%2.20%1.12%
1 Year Performance2.94%-3.04%5.02%21.80%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.5307 of 5 stars
$807.86
+0.1%
$769.53
-4.7%
+90.9%$767.39B$34.12B118.9843,000Insider Selling
NVO
Novo Nordisk A/S
1.7563 of 5 stars
$134.08
-1.4%
$133.60
-0.4%
+225.7%$610.48B$33.71B46.2363,370Analyst Forecast
JNJ
Johnson & Johnson
4.8307 of 5 stars
$144.40
-1.7%
$175.86
+21.8%
-6.4%$353.71B$85.16B9.00131,900Analyst Forecast
MRK
Merck & Co., Inc.
4.0921 of 5 stars
$126.11
-2.6%
$131.33
+4.1%
+13.4%$327.97B$60.12B140.1272,000Dividend Announcement
News Coverage
ABBV
AbbVie
4.776 of 5 stars
$155.37
-1.1%
$176.14
+13.4%
+12.6%$277.35B$54.32B46.1050,000Short Interest ↑
Analyst Revision
AZN
AstraZeneca
2.3803 of 5 stars
$76.62
-2.4%
$82.00
+7.0%
+4.9%$243.51B$45.81B37.5689,900Analyst Forecast
Short Interest ↓
ABT
Abbott Laboratories
4.9397 of 5 stars
$101.95
-1.9%
$120.60
+18.3%
-2.1%$180.83B$40.11B31.76114,000Analyst Forecast
PFE
Pfizer
4.8264 of 5 stars
$28.32
-1.9%
$35.86
+26.6%
-26.0%$163.65B$58.50B-471.8488,000
SNY
Sanofi
3.1345 of 5 stars
$47.94
-1.2%
$55.00
+14.7%
-9.4%$122.80B$46.61B24.0986,088Short Interest ↓
Analyst Revision
VRTX
Vertex Pharmaceuticals
4.0228 of 5 stars
$446.88
-2.2%
$432.18
-3.3%
+33.7%$117.92B$9.87B29.005,400Analyst Downgrade
Insider Selling

Related Companies and Tools

This page (NYSE:NVS) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners